Angela R. Jones-Leone

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

Michael A. Nauck, Murray Stewart, Christopher Perkins et al. · Diabetologia · 2015 · 121 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study

Lawrence A. Leiter, Molly C. Carr, Murray Stewart et al. · Diabetes Care · 2014 · 91 citations

Medicine, Pharmacology, Pharmacotherapy +17

A randomized, parallel group, double‐blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long‐term glycaemic control and bone mineral density after 80 weeks of treatment in drug‐na <i>ï</i> ve type 2 diabetes mellitus patients

João Borges, John P. Bilezikian, Angela R. Jones-Leone et al. · Diabetes Obesity and Metabolism · 2011 · 90 citations

Medicine, Endocrinology, Pharmacology +17

40th EASD Annual Meeting of the European Association for the Study of Diabetes

M. Veitenhansl, K. Stegner, F. X. Hierl et al. · Diabetologia · 2004 · 68 citations · Full text

Medicine, Endocrinology, Diabetology +11

Albiglutide does not impair the counter‐regulatory hormone response to hypoglycaemia: a randomized, double‐blind, placebo‐controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus

Marcus Hompesch, Angela R. Jones-Leone, Molly C. Carr et al. · Diabetes Obesity and Metabolism · 2014 · 31 citations

Medicine, Endocrinology, Pharmacology +17